Hypolipidemic Therapy and HDL
Year: 2010
Type: article
Abstract: ABSTRA C T Statins significantly reduce cardiovascular events by reducing low-density-lipoprotein cholesterol (LDL-C). However, despite achieving the LDL goals, a substantial residual risk remains. It appears that low levels of high-density lipoprotein cholesterol (HDL-C) constitute another independent risk factor for coronary artery disease (CAD). Therefore, raising HDL levels appears an attractive target to further reduce the cardiovascular risk. However, classical HDL-reducing drugs (nicotinic acid derivatives, fibrates) are not well tolerated and newer agents (torcetrapid), which seemed effective in doing that, had to be withdrawn due to increased mortality. Nevertheless, due to the importance of HDL in influencing the cardiovascular risk, efforts in developing safer drugs are continuing. Such pharmacological developments, as well as the nonpharmacological approaches to increase HDL, and other HDL-targeted therapies are discussed in this overview.
Author: Ioannis Chaveles
Institution: Evangelismos Hospital
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W1923458054